Praxis Precision Medicines, Inc. (PRAX)
Stock Price:
$27.25 USD
-0.55 (-1.98%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $27.45 +0.20 (0.73%) Oct 19, 7:58 PM
Key Info
| Market Cap |
1.00B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-44.49M |
| Shares Out |
36.74M |
| EPS (ttm) |
-1.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$27.25 |
| Previous Close |
$27.80 |
| Change ($) |
-0.55 |
| Change (%) |
-1.98% |
| Day's Open |
27.21 |
| Day's Range |
26.50 - 29.02 |
| Day's Volume |
285,112 |
| 52-Week Range |
25.50 - 30.82 |
More Stats
| Market Cap |
1.00B |
| Enterprise Value |
982.20M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
36.74M |
| Float |
18.04M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.21 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-44.49M |
| Free Cash Flow |
n/a |
| Net Cash |
19.23M |
| Net Cash / Share |
0.52 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -35.79 | -22.72 |
| Net Income | -35.51 | -26.54 |
| Shares Outstanding | 1.53 | 1.30 |
| Earnings Per Share | -26.60 | -22.52 |
| Operating Cash Flow | -33.42 | -20.72 |
| Capital Expenditures | -0.10 | -0.06 |
| Free Cash Flow | -33.52 | -20.78 |
| Cash & Equivalents | 45.42 | 18.55 |
| Total Debt | 1.46 | - |
| Net Cash / Debt | 43.96 | 18.55 |
| Assets | 47.69 | 19.83 |
| Liabilities | 7.58 | 5.15 |
| Book Value | -81.01 | -41.04 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Praxis Precision Medicines, Inc. |
| Country |
United States |
| Employees |
42 |
| CEO |
Marcio Souza |
Stock Information
| Ticker Symbol |
PRAX |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Pharmaceuticals: Major |
| Unique Identifier |
NASDAQ: PRAX |
| IPO Date |
October 16, 2020 |
Description
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. We are applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. We apply a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. We have three product candidates currently in clinical development. We intend to develop differentiated therapies that can deliver long-term benefits to human health by meaningfully impacting patients and society. Our insights into genetic mutations resulting in neuronal imbalance have enabled us to develop a pipeline addressing prevalent psychiatric and neurologic conditions and rare diseases, with the ability to expand into additional indications.